Samyang Biopharm USA, a global biotech subsidiary of Samyang Holdings Corp., said on Thursday that it appointed Ryu Eun-ju as its new CEO.
Ryu is a new drug business strategist and marketing expert with more than 30 years of experience in global clinical trial management and drug approval, business development, and global marketing at multinational pharmaceutical companies.
She graduated from Ewha Womans University majoring in pharmacy, received a Master’s in clinical pharmacy at Sookmyung Women’s University, and an MBA degree at New York University.
After working as head of oncology and specialty business unit at Pfizer Korea, she moved to Pfizer’s headquarters in New York as a Japan Asia regional commercial lead in 2006. She also served as Pfizer's emerging market portfolio acquisition director and global marketing director.
Ryu also led global clinical trials and new business development at Bayer Korea and a U.S. medical device company.
The Ministry of Health and Welfare awarded Ryu for her contribution to the pharmaceutical industry cooperation between Korea and the U.S.
“CEO Ryu has core competence in establishing global strategies for oncology and rare disease and commercialization,” said Lee Young-joon, head of Biopharm Group at Samyang Holdings. “Based on her capabilities and experiences, she will contribute to the growth of Samyang Biopharm USA.”
Ryu said she was pleased to serve as president of Samyang Biopharm USA, which strives to build its pipeline in select oncology indications to provide innovative drugs for patients.
“By securing new R&D pipelines and expanding business portfolio, I will drive growth over the long term,” she said.